ArticleJournal of cancer research and clinical oncology2026
Minimizing the risks of stereotactic brain biopsy in suspected central nervous system lymphoma: a retrospective database study.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic brain biopsy is widely used to confirm the diagnosis of central nervous system (CNS) lymphoma; however, few studies have investigated the perioperative factors that impact the procedure’s clinical utility and outcome.
methodWe retrospectively reviewed all patients at our institution who underwent brain biopsy and were confirmed to have CNS lymphoma diagnosis in years 2001–2021. Clinical history, imaging, intraoperative data, and post-biopsy outcomes were obtained. Associations between perioperative factors and postprocedural morbidity/mortality were analyzed using univariate and multivariate models.
resultsCNS lymphomas were diagnosed in 75 patients via 79 separate biopsies, of which 12 (16%) had a prior diagnosis of lymphoma (CNS or systemic). Postoperative 30-day mortality was 8.9%. Intraoperative bleeding was noted in 6 patients (7.6%), postoperative hemorrhage in 4 patients (5.1%). We identified several factors leading to poor outcomes. Biopsy of deep-brain structures (thalamus and basal ganglia) was associated with higher rates of postoperative hemorrhage (17.6% vs. 1.6%, p = 0.030) and discharge to hospice (35.3% vs. 9.7%, p = 0.018). Biopsy at multiple depths, a modifiable risk factor, was associated with worse survival after multivariate analysis (p = 0.036). In patients with a history of systemic diffuse large B-cell lymphoma (DLBCL), all brain biopsies diagnosed DLBCL; several patients with non-DLBCL were diagnosed with other pathologies including glioblastoma.
conclusionSeveral variables were associated with poor outcomes after biopsy for suspected CNS lymphoma. Our findings support avoiding biopsy of multiple depths unless critical. These factors should be considered and further risk stratification for patient selection is necessary to optimize the clinical utility of brain biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.